We're raising our price target on Eli Lilly as the obesity-drug boom rolls on
The Lilly train keeps on rolling thanks to Mounjaro and Zepbound. And there's more growth to be had.
This is a summary aggregated from CNBC. Read the complete article on the original site:
Read full article at CNBC
